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ABSTRACT: The control of malaria is challenged by drug
resistance, and new antimalarial drugs are needed. New drug
discovery eﬀorts include consideration of hybrid compounds
as potential multitarget antimalarials. Previous work from our
group has demonstrated that hybrid structures resulting from
cinnamic acid conjugation with heterocyclic moieties from
well-known antimalarials present improved antimalarial
activity. Now, we report the synthesis and SAR analysis of
an expanded series of cinnamic acid derivatives displaying
remarkably high activities against both blood- and liver-stage
malaria parasites. Two compounds judged most promising,
based on their in vitro activity and druglikeness according to
the Lipinski rules and Veber ﬁlter, were active in vivo against
blood-stage rodent malaria parasites. Therefore, the compounds reported represent a new entry as promising dual-stage
antimalarial leads.
■ INTRODUCTION
Several concerted eﬀorts to control malaria and achieve its
eradication have been made through history.1 Despite initial
success, with regional elimination in Southern Europe and
some countries in North Africa and the Middle East, malaria
has not been controlled in many other countries because of a
number of factors.2 Two main reasons for malaria remaining
such a burden to humanity are the widespread resistance of the
malaria parasite to available drugs and its complex life cycle.2
Human malaria is triggered by infection by an intracellular
Plasmodium parasite, which is transmitted to human hosts via
an infected female Anopheles mosquito bite. Once in the host
circulation, Plasmodium sporozoites initiate the asexual phase of
the life cycle by quickly moving to the liver. During this
clinically silent liver-stage infection, thousands of merozoites
are formed and released into the bloodstream, where they
invade red blood cells, thus starting the pathogenic asexual
erythrocytic cycle, resulting in the various clinical manifes-
tations of malaria.3
Resistance of malaria parasites to previous generations of
medicines, such as chloroquine (1), became widespread in the
1970s and 1980s, undermining malaria control eﬀorts. During
the past decade, artemisinin-based combination therapies
(ACTs) have been adopted globally as the ﬁrst line of
treatment. ACTs include a rapidly acting artemisinin
component and a partner drug to improve eﬃcacy and hinder
emergence of resistance to artemisinins.4 However, there are
now worrisome signs that malarial parasites are developing
resistance to artemisinins (2),5 and so the dependence of all
new drug combinations on artemisinin derivatives is a matter of
concern. While most available antimalarial agents target the
blood-stage parasites, relatively few drugs are known to inhibit
liver stage parasites. Primaquine (3) remains the only drug in
clinical use worldwide that acts against liver stages of all
Plasmodium species,6 including P. vivax and P. ovale
hypnozoites, which are latent forms unique to these species
that cause relapsing malaria long after the original infection,
complicating control eﬀorts.7,8 Taking into account concerns of
drug resistance and diﬃcult-to-treat chronic liver stages,
optimal therapy should be eﬀective against multidrug-resistant
parasite strains and be active against both liver and erythrocytic
parasite stages.
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A recent approach in antimalarial drug design characterized
as “covalent bitherapy” involves linking two active molecules,
thus packaging dual activity into a single hybrid molecule with
potential to enhance eﬃcacy, improve safety, and/or reduce
propensity to elicit resistance relative to the parent drugs.9,10 As
part of our eﬀorts to develop novel hybrids, we previously
reported a ﬁrst generation of heterocycle−cinnamic acid
conjugates (4 and 5, Figure 1) linking the heteroaromatic
ring of known antimalarials to a trans-acid cinnamic motif,
active in vitro against blood-stage P. falciparum.11 From these
studies we discovered that a spacer between the heterocycle
and the cinnamoyl moiety is required for antiplasmodial activity
and that the higher the lipophilicity of conjugates 4, the higher
is their in vitro antiplasmodial activity. On the basis of these
results, we developed a second generation of conjugates (7 and
8, Figure 1) where the cinnamoyl core was linked to the
heterocyclic core of known antimalarials through a ﬂexible and
more hydrophobic butylamine chain.12,13 Compounds 7 (IC50
against cultured malaria parasites of 11−59 nM)13 and 8 (IC50
= 1.4−2.4 μM)12 had higher in vitro potency than their parent
compounds 1 (IC50 = 138 nM) and 3 (IC50 = 7.5 μM), against
blood-stage P. falciparum (W2 strain) and liver-stage P. berghei.
These ﬁndings established the cinnamoyl core as a valuable
pharmacophore to enhance potency of established antima-
larials.
Building on these compounds, we have performed further
SAR studies and herein report the synthesis and antimalarial
assessment of a series of new heterocycle−cinnamic conjugates
(in brief, HEFLECINs). In terms of SAR, the presence of
aromaticity in the heterocyclic core, the number of the
heteroaromatic rings, the length of the aliphatic chain, the
nature (amide or ester) of the linkage between the heterocycle
and cinnamic core, and the nature of the cinnamic substituent
were all evaluated (Figure 2). Compounds were tested in vitro
against erythrocytic stages of the human parasite P. falciparum;
two of them, 7d and 7h, were further conﬁrmed to be active in
vivo against the clinically relevant blood-stage infection in a P.
berghei rodent malaria model. Additionally, our recent ﬁndings
on the improved liver-stage antimalarial activity of N-cinnamoyl
derivatives of primaquine12 prompted us to evaluate the activity
of heterocycle−cinnamic conjugates against liver-stage P.
berghei parasites. Most of the HEFLECINs were structurally
related to chloroquine, presented outstanding activity against
both erythrocytic and liver stages of the parasite life cycle, and
were noncytotoxic against Huh7 human hepatoma cells. To the
best of our knowledge, chloroquine-related compounds active
against both liver- and blood-stage parasites have not previously
been reported. These results bring new insights into the
development of dual action antimalarial agents.
■ RESULTS AND DISCUSSION
Chemistry. For the past decade we have been working on
the design, synthesis, and evaluation of potential antimalarial
candidates, bearing in mind that synthetic pathways should be
kept as cheap and straightforward as possible. The
HEFLECINs reported here are examples of how simple
chemistry can yield promising antimalarial leads (Scheme 1).
Figure 1. Chemical structures of chloroquine (1), artemisinin (2), primaquine (3), and ﬁrst- (4 and 5) and second- (7 and 8) generation
heterocycle−cinnamic acid conjugates.
Figure 2. Structural parameters considered in the SAR analysis of the
heterocycle−cinnamic acid conjugates.
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Compound 8d was obtained through a single amide coupling
step between the parent drug PQ (3) and the desired cinnamic
acid, using previously reported standard peptide coupling
conditions,12 namely, activation of the cinnamic acid with O-
(benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium tetraﬂuoro-
borate (TBTU) in the presence of N-ethyl-N,N-diisopropyl-
amine (DIEA), followed by addition of PQ. Compounds 713
and 9−13 were obtained in two steps, starting from (i) a
classical nucleophilic aromatic substitution reaction between
the appropriate diaminoalkane (1,3-diaminopropane, 1,4-
diaminobutane, or 1,5-diaminopentane) or 4-aminobutan-1-ol
(in the synthesis of 11) and the desired chlorinated heterocycle
(4,7-dichoroquinoline, 4-chloroquinoline, or 4-chloropyridine)
followed by (ii) coupling the resulting compounds to the
appropriate cinnamic acids, again conveniently activated by
TBTU/DIEA. The synthesis of 14 was the only one requiring
three steps, as (i) morpholine was ﬁrst reacted with 1-(N-
phthaloyl)amino-4-bromobutane followed by (ii) hydrazinol-
ysis of the phthaloyl amino-protecting group to aﬀord the free
amine for subsequent (iii) PyBOP/DIEA-mediated coupling to
the appropriate cinnamic acid.
Although not all synthesis yields were high, the rather small
number of synthesis steps, cheap starting materials, and
straightforward puriﬁcation techniques (cf. Experimental
Section) largely compensate for low yields. All the target
compounds where obtained in high purity, as determined by
high performance liquid chromatography with diode array
detection (HPLC-DAD), and their structures were conﬁrmed
by proton (1H) and carbon-13 (13C) nuclear magnetic
resonance (NMR), as well as by mass spectrometry (MS)
analysis with electrospray ionization and ion-trap quadrupole
detection (ESI-IT). Relevant data are presented in the
Experimental Section.
Biology. Our recent discovery of the potent in vitro activity
of CQ analogues 7 against blood-stage CQ-resistant P.
falciparum parasites unveiled the key role of the cinnamoyl
moiety in reversing parasite resistance to CQ.13 We have now
expanded the family of heterocycle−cinnamic acid conjugates
(HEFLECINs) and tested their in vitro activity against blood-
stage P. falciparum (Table 1) in order to (i) establish relevant
SAR (Figure 2) and (ii) select the most promising candidates
for in vivo challenge in the P. berghei rodent malaria model. For
some of the compounds we compared activity against
chloroquine-sensitive (3D7) and -resistant (W2) P. falciparum
parasites. Furthermore, given their structural analogy to CQ,
which acts via inhibition of β-hematin formation, selected
compounds were evaluated as in vitro inhibitors of this process
(Table 1).14,15 Finally, on the basis of our latest disclosure of
primaquine−cinnamic acid conjugates (PRIMACINs) with
improved in vitro activity against liver-stage Plasmodia,12 we
also assessed the in vitro activity of a subset of the HEFLECINs
against liver-stage P. berghei (Figure 3, Table 1).
In Vitro Activity against Intraerythrocytic P. falcipa-
rum Parasites. Blood-stage activity of HEFLECINs was
determined by methods previously reported by us.16,17 Close
inspection of our data (Table 1, columns 8 and 9) shows the
following.
(i) Remarkably, most of the test compounds assayed against
both strains were more active against the CQ-resistant (W2)
strain than against the CQ-sensitive (3D7) strain.
(ii) Compounds from the 7, 9, and 10 series with a single
substituent (R) on the cinnamoyl group (i.e., all except 7p)
Scheme 1. Synthetic Pathways toward Heterocycle−Cinnamic Acid Conjugates 7 and 9−12
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were highly active, with IC50 in the range 11−79 nM. These
series diﬀer only in the length of the polymethylene spacer
between the chloroquinoline and cinnamoyl cores. Comparison
between homologues from series 7, 9, and 10 (i.e., 7c vs 9c vs
10a, or 7h vs 9h vs 10c, or 7d vs 9d vs 10b) shows that a butyl
spacer is preferred over pentyl and propyl spacers.
(iii) Removal of the 7-chlorine substituent from the
chloroquinoline ring leads to a decrease in antimalarial activity
of about 1 order of magnitude, as shown for compounds 7c
(IC50 = 11 nM) and its dechlorinated analogue 12 (115 nM).
(iv) Replacement of the amide bond in 7d (IC50 = 20 nM)
by its ester isostere, to aﬀord 11, leads to a 6-fold decrease in
activity (122 nM).
Table 1. In Vitro Data on Test Compounds for β-Hematin Inhibition, and Blood- and Liver-Stage Activity
compd HET n X R2 R3 β-hematin inhibitiona Pf W2 IC50 (nM)
b Pf 3D7 IC50 (nM)
b liver stage IC50 (μM)
c,g
7a Cq R1 = Cl 2 N H H NA 46.6 ± 5.5 62.85 ± 3.5 1.06 ± 0.1
7b p-Me NA 16.9 ± 1.2 24.23 ± 0.2 2.36 ± 0.5
7c p-iPrc + 11.0 ± 6.2 15.63 ± 5.4 2.50 ± 0.2
7d p-OMec + 20.0 ± 2.6 30.63 ± 9.5 2.86 ± 0.4
7e p-NH2 NA 58.8 ± 1.5 78.12 ± 2.2 ND
7f m-F + 34.1 ± 4.2 50.92 ± 1.0 1.13 ± 0.2
7g p-F + 19.7 ± 0.4 39.85 ± 3.5 1.42 ± 0.2
7h p-Cld + 11.6 ± 0.4 26.21 ± 2.0 1.44 ± 0.3
7i p-Br ++ 18.2 ± 2.8 28.75 ± 6.3 2.28 ± 0.6
7j o-NO2 + 38.3 ± 4.2 56.91 ± 5.1 1.09 ± 0.2
7k m-NO2 NA 26.2 ± 5.0 42.06 ± 7.1 ND
7l p-NO2 ++ 23.5 ± 1.3 48.94 ± 3.2 ND
7o p-NMe2 + 25.8 ± 2.1 ND ND
7p m,p-di-OMe NA 110.8 ± 13.0 ND 4.05 ± 0.2
8d Pq 2 N CH3 p-OMe >10000
h 2.35 ± 0.19h
9a Cq R1 = Cl 1 N H H NA 74.8 ± 2.0 141.3 ± 9.3 ND
9b p-Me NA 47.4 ± 1.2 55.85 ± 5.1 ND
9c p-iPr NA 38.0 ± 11.2 50.27 ± 1.0 ND
9d p-OMe NA 55.1 ± 2.3 49.51 ± 5.8 4.02 ± 0.6
9e p-NH2 NA 79.8 ± 2.0 134.85 ± 5.4 ND
9f m-F NA 73.3 ± 6.8 137.95 ± 1.2 ND
9g p-F NA 46.7 ± 3.3 47.73 ± 1.3 ND
9h p-Cl + 41.6 ± 2.9 46.47 ± 4.5 ND
9i p-Br NA 38.2 ± 6.9 49.96 ± 3.5 ND
9j o-NO2 + 52.1 ± 4.0 64.15 ± 6.7 ND
9k m-NO2 + 50.3 ± 1.2 52.73 ± 5.3 ND
9l p-NO2 + 23.7 ± 2.1 52.53 ± 10.8 ND
10a Cq R1 = Cl 3 N H p-iPr + 31.5 ± 3.8 ND ND
10b p-OMe NA 50.3 ± 2.6 ND 2.27 ± 0.6
10c p-Cl NA 25.1 ± 0.2 ND 1.62 ± 0.1
11 Cq R1 = Cl 2 O H p-OMe + 121.9 ± 5.5 ND 6.47 ± 0.9
12 Cq R1 = H 2 N H p-iPr NA 114.9 ± 3.0 ND ND
13 Py 2 N H p-OMe NA >10000 ND >10
14 Mu 2 N H p-iPr NA >10000 ND >10
ART − 9.5 ± 1.9 23.5 ± 0.8 ND
CQ ++ 138e 52.45 15.9 ± 0.0
PQ 3300f 7.5h
aAbility of the test compounds to inhibit hemozoin formation in vitro was calculated as a percent of the inhibitory eﬀect displayed by reference drug
CQ in the same experiment. Test compounds were ranked as follows: <50%, not active (−); between 50% and 75%, moderately active (+); ≥75%,
highly active (++). bBlood-stage antiplasmodial activity was determined against the CQ-resistant P. falciparum strain W2 and strain 3D7, using
artemisinin (ART) and CQ as reference drugs. cIC50 of the most active compounds against liver stage.
dAlso tested in vivo. eValue taken from ref 24.
fValue taken from ref 17. gND, not determined. hValue taken from ref 12.
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(v) Substitution of the chloroquinoline ring (e.g., 7d, IC50 ≈
20 nM) by another heteroaromatic ring, quinolinic (8-amino-6-
methoxyquinoline ring in 8d), pyridinic (single heteroaromatic
pyridine ring in 13), or nonaromatic (morpholine ring in 14),
leads to complete loss of activity.
(vi) Comparison of IC50 values within a given series, e.g., 7
or 9, shows that the cinnamoyl substituent R has some eﬀect on
activity but that this eﬀect is not dramatic. The electro-
donating/withdrawing character of R seems to have no
signiﬁcant role in activity, whereas the para position is clearly
preferred over the ortho and meta positions, as shown for 7k−l
and 9k−l.
(vii) Increase in compound lipophilicity and/or the bulkiness
of R within a series seems to enhance in vitro activity. We
previously showed that IC50 values for 7 showed good
correlation with both clogP values and Charton parameters.13
For the new 9 series, we observed a good correlation with
Charton parameters but not clogP values (cf. Table S1 in
Figure 3. Survival curves for P. berghei infected mice treated with compounds 7c, 7d, and 7h and CQ.
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Supporting Information). Series 10 was too small to allow
drawing of deﬁnitive conclusions in this regard.
(viii) Finally, HEFLECINs bearing the chloroquinoline core
were globally more active than CQ, whereas the two most
active compounds, 7c and 7h, had activities comparable to that
of artemisinin. Therefore, these two compounds, as well as 7d,
the most active compound within the series satisfying the
leadlikeness,18 Lipinski19 and Veber20 ﬁlters, were selected for
in vivo studies with P. berghei.
In Vitro Activity against β-Hematin Formation. The
ability of HEFLECINs to inhibit β-hematin formation to
hemozoin, the main mechanism attributed to CQ and related
antimalarials, was assessed by previously reported methods.11
This activity was not fully correlated with in vitro antimalarial
activities (Table 1), suggesting that HEFLECINs owe their
antimalarial properties to mechanisms in addition to inhibition
of β-hematin crystallization. Nonetheless, we believe that
inhibition of β-hematin formation contributes to activity
because (i) variation of β-hematin inhibition potency among
homologues, e.g., 7c, 9c, and 10a, follows the same trend as
variation of activities against blood-stage parasites and (ii) the
signiﬁcant decrease in antimalarial activity upon removal of the
7-chlorine substituent (7c vs 12) may be explained by the prior
observation that this chlorine atom is essential to ensure
eﬀective β-hematin inhibition by CQ and related structures.21,22
On the basis of previous and current ﬁndings, it is concluded
that HEFLECINs do not act against blood-stage parasites via
inhibition of the cysteine protease falcipains.13 Activity may
include impairment of the new permeation pathways (NPPs)
created by Plasmodia in the infected red blood cell (RBC)13
and inhibition of β-hematin crystallization.
In Vivo Treatment of P. berghei Infected Mice. For the
three most promising HEFLECINS, in vivo eﬃcacy was
evaluated using a standard P. berghei mouse model.
Compounds chosen for in vivo analysis were 7c and 7h
because of their potency against cultured blood-stage P.
falciparum and 7d because of its better druglikeness. Mice
were infected intraperitoneally (ip) with P. berghei and then
Figure 4. Activity of HEFLECINs against P. berghei liver stages. Anti-infective activity (infection scale, y-axis) and toxicity to hepatoma cells (cell
conﬂuency scale, x-axis) are shown. Primaquine (PQ) and chloroquine (CQ) were included for comparison. The black, red, and blue circles
represent results for the tested compounds at 10, 5, and 1 μM, respectively. Infection loads of Huh7 cells, from a human hepatoma cell line, were
determined by bioluminescence measurements of cell lysates 48 h after infection with luciferase-expressing P. berghei parasites.25
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treated twice daily with ip injections of 10, 30, and 100 mg/kg.
Chloroquine was used as a positive control at 3, 10, and 30 mg/
kg ip twice daily. All mice died because of malaria or toxicity by
day 17 at the doses administered. In order to compare
compound eﬃcacies, survival over time after the initiation of
treatment was compared.
Close inspection of the data leads to the following
observations (Figure 3). Compounds 7c and 7h were highly
toxic at 100 mg/kg, and no mice survived until the last day of
treatment. At lower dosages, 7h extended survival compared to
untreated controls by 2−7 days at 30 mg/kg and by 2 days at
10 mg/kg. Compound 7c did not improve survival compared to
untreated controls. Compound 7d did not appear to be toxic at
any tested dosage. It extended survival by 2 days compared to
untreated controls at the highest dosage but oﬀered no beneﬁt
over untreated controls at the lower dosages.
Studies with the rodent malaria model conﬁrmed that 7d and
7h have in vivo antimalarial activity. The lack of in vivo activity
of 7c can be attributed to its high lipophilicity (clogP > 5; see
Table S1 in Supporting Information),19 but compounds 7d and
7h are only slightly less lipophilic (clogP ≈ 5; see Table S1 in
Supporting Information) than 7c. However, in vivo activities
for 7d and 7h were lower than might be expected based on
their in vitro activities, possibly because of limitations in
bioavailability. Additionally, relatively poor performance of the
compounds in vivo might be explained by biological diﬀerences
between P. berghei and P. falciparum and by the high
hydrophobicity of the compounds, which might result in
extensive binding to plasma proteins.23
In Vitro Activity against Liver-Stage P. berghei
Parasites. Recent ﬁndings from our group, demonstrating
that the liver-stage activity of PQ is signiﬁcantly enhanced by
conjugation with cinnamic acids, prompted us to investigate
whether HEFLECINs would also exhibit liver-stage activity,
measured using P. berghei as previously reported.12,17,25 We
found that HEFLECINs bearing the chloroquinoline core of
CQ (7, 9, 10) were all active against liver stage parasites. This
result was surprising, as CQ is not active against liver-stage
malaria.26 In view of these results, the activities of compounds
selected as most promising based on activity and cytotoxicity
were compared quantitatively (Figure 4, Table 1). Remarkably,
activities were much higher than those observed for either CQ
or PQ. Speciﬁcally, IC50 values were 5−15 times lower than
those for CQ and 3−7 times lower than those for the reference
drug PQ. This is, to our knowledge, the ﬁrst report of 4-amino-
7-chloroquinolinic (CQ-related) structures displaying in vitro
activity against liver-stage Plasmodia greater than that of PQ.
This ﬁnding, together with the previous observation that N-
cinnamoylation of PQ also enhances its in vitro activity against
liver-stage Plasmodia,12 strongly suggests that the N-cinnamoyl
moiety is a relevant pharmacophore to boost antiplasmodial
activity in both 8- and 4-aminoquinolines. Some SARs could be
devised from the liver-stage assays, as follows.
(i) As in blood-stage activity assays, a butyl spacer between
the chloroquinoline and the cinnamic cores is generally
preferred over propyl and pentyl spacers, in terms of both
activity and toxicity, as inferred from comparison of
homologues from series 7, 9, and 10.
(ii) Unlike what was observed in blood-stage activity assays,
substitution of the cinnamoyl aromatic ring in series 7 led to
slightly decreased activity; i.e., the most active compound was
7a, where R = H.
(iii) The presence of electrodonating R groups in the para
position led to a decrease in activity.
(iv) An increase of the number of OMe substituents on the
cinnamoyl core from 1 (7d) to 2 (7p) led to a decrease in
toxicity but also in activity.
(v) Removal of the 7-chlorine atom from the chloroquinoline
ring led, as observed for blood-stage activity, to a decrease in
liver-stage activity.
(vi) Also, as observed against blood-stage Plasmodia,
replacement of the chloroquinoline ring by pyridine or
morpholine led to loss of activity against liver-stage parasites.
As is the case for PQ, the mechanism of HEFLECINs against
liver-stage Plasmodia remains to be elucidated.12 Studies are
underway to establish the target(s) of HEFLECINs against
liver- and blood-stage parasites. The discovery that HEFLE-
CINs bearing the CQ heterocyclic core, unlike their PQ
analogues (PRIMACINs12), combine signiﬁcant liver-stage
activity with potent blood-stage activity is of great interest.
To our knowledge, this is the ﬁrst example of CQ-related
molecules emerging as multistage antimalarial leads.
■ CONCLUDING REMARKS
A new family of chloroquine analogues, HEFLECINS, as dual-
stage antimalarial leads was found. These compounds display
potent in vitro activity against both liver- and blood-stage
Plasmodia, including chloroquine-resistant blood-stage P.
falciparum W2 parasites. All of them performed better than
chloroquine itself in vitro on both stages, and the best couple of
compounds, 7c and 7h, were equipotent to artemisinin on
blood-stage parasites. Further, all but 11, 13, and 14 were better
than primaquine on liver-stage parasites. Relevantly, both
blood- and liver-stage activities were lost upon replacement of
the 4-amino-7-chloroquinoline ring with either a nonaromatic
(i.e., morpholine) or an aromatic (i.e., 4-aminopyridine)
heterocycle, while replacement with the primaquine’s 8-
amino-6-methoxyquinoline moiety only eliminated blood-
stage activity. This demonstrates that the 4-amino-7-chlor-
oquinoline motif has a critical role for the display of dual-stage
antimalarial activity. Two of the most promising compounds
were conﬁrmed to be active against the murine model of
malarial infection, even though with modest in vivo perform-
ances compared to in vitro ones. This is possibly due to
bioavailability issues requiring future optimization of the
reported antimalarial leads. Studies on the possible mecha-
nism(s) underlying dual-stage activity displayed by the N-
cinnamoylated chloroquine analogues are underway. Falcipain
inhibition has been ruled out, whereas blocking of β-hematin
formation cannot fully account for the activity levels observed.
The role of these antimalarial leads as blockers of ion channels
speciﬁc to infected host cells, like the so-called NPP created in
P. falciparum-infected RBC, is presently under investigation.
Overall, data show that N-cinnamoylation of chloroquine
enhances the parent drug’s activity against both blood- and
liver-stage Plasmodia, which is the ﬁrst example of chloroquine-
derived molecules with multistage antimalarial activity. This
ﬁnding, along with the recent disclosure of an apparent
resusceptibilization of P. falciparum to chloroquine in Nigeria,30
may have relevant impact on the reactivation of chloroquine
manufacturers, especially in African countries like Ghana, in
which chloroquine production has been halted because of the
well-known parasite resistance to this drug.31
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■ EXPERIMENTAL SECTION
Chemistry. Chemicals and Instrumentation. All solvents and
common chemicals were from Sigma-Aldrich (Spain), whereas Boc-
protected amino acids were from NovaBiochem (VWR International,
Portugal) and the coupling agent TBTU was from Bachem
(Switzerland). NMR spectra were acquired on a Bruker Avance III
400 spectrometer from solutions in either deuterated chloroform or
deuterated dimethylsulfoxide (DMSO-d6) containing tetramethylsilane
as internal reference. Mass spectrometry (MS) analyses were run on a
Thermo Finnigan LCQ Deca XP Max LC/MSn instrument operating
with electrospray ionization and ion-trap (ESI-IT) quadrupole
detection. The target compounds were conﬁrmed to have at least
95% purity, based on peak areas obtained through HPLC analyses that
were run using the following conditions: 30−100% of B in A (A =
H2O with 0.05% of triﬂuoroacetic acid; B = acetonitrile) in 22 min
with a ﬂow rate of 1 mL/min on a Merck-Hitachi Lachrom Elite
instrument equipped with a diode array detector (DAD) and
thermostated (Peltier eﬀect) autosampler, using a Purospher STAR
RP-18e column (150 mm × 4.0 mm; particle size, 5 μm).
Synthesis of Compounds 7−10. Compounds 7a−l and 8 were
prepared by previously described methods, and their analytical and
structural data were in perfect agreement with formerly reported
data.12,13 Compounds 7o,p were prepared identically to 7a−l, and
their spectroscopic data were compatible with the respective
structures, as follows.
4-[N-(p-Dimethylamino)cinnamoylaminobutyl]amino-7-
chloroquinoline (7o). White solid (14 mg, 8%); mp = 176−180 °C;
Rf (DCM/MeOH 8:2) 0.44; δH (400 MHz, DMSO-d6) 8.39 (d, J = 5.6
Hz, 2H), 8.32 (d, J = 8.8 Hz, 1H), 7.95 (m, 1H), 7.79 (d, J = 2 Hz,
1H), 7.62 (m, 1H), 7.47 (dd, J = 8.8, 2.4 Hz, 1H), 7.36 (d, J = 8.8 Hz,
2H), 7.29 (d, J = 16 Hz, 1H), 6.70 (d, J = 8.8 Hz, 2H), 6.53 (d, J = 5.6
Hz, 1H), 6.35 (d, J = 16 Hz, 1H), 3.32 (m, 2H), 3.22 (m, 2H), 2.94 (s,
6H), 1.68 (m, 2H), 1.57 (m, 2H); δC (100 MHz, DMSO-d6) 165.6,
150.9, 150.7, 150.6, 147.6, 138.8, 133.9, 128.7, 126.3, 124.3, 122.3,
117.1, 116.7, 111.9, 98.6, 42.1, 38.1, 26.9, 25.1. ESI-IT MS: m/z (M +
H+) 423.47, M+ (C24H27ClN4O) requires 422.19. HPLC-DAD: tR =
11.7 min, % area = 96.0.
4-[N-(m,p-Dimethoxy)cinnamoylaminopropyl]amino-7-
chloroquinoline (7p). White solid (29 mg, 17%); mp = 168−172
°C; Rf (DCM/MeOH 8:2) 0.44; δH (400 MHz, DMSO-d6) 8.41 (d, J
= 5.6 Hz, 1H), 8.36 (d, J = 9.2 Hz, 1H), 8.06 (m, 1H), 7.81 (m, 2H),
7.50 (dd, J = 9.4 Hz, 2.4 Hz, 1H), 7.34 (d, J = 16 Hz, 1H), 7.10 (m,
2H), 6.96 (d, J = 8.4 Hz, 1H), 6.57 (d, J = 5.6 Hz, 1H), 6.51 (d, J = 16
Hz, 1H), 3.78 (s, 3H), 3.77 (s, 3H), 3.35 (m, 2H), 3.23 (m, 2H), 1.69
(m, 2H), 1.57 (m, 2H); δC (100 MHz, DMSO-d6) 165.2, 151.2, 150.0,
149.8, 148.8, 146.6,138.4,134.3, 127.6, 125.5, 124.5, 124.4, 121.2,
119.9, 116.9, 111.7, 109.9, 98.6, 55.4, 55.3, 42.2, 38.2, 26.7, 25.1. ESI-
IT MS: m/z (M + H), M+ (C24H26ClN3O3) requires 439.17. HPLC-
DAD: tR = 12.5 min, % area = 100.
Compounds 9 and 10 were synthesized by methods similar to those
previously described for compounds 7.13 Brieﬂy, 4,7-dichloroquinoline
(1 equiv, 1.2 mmol) was reacted with the appropriate diaminoalkane
(10 equiv, 12 mmol) at 100 °C for 3 h. The mixture was brought to
room temperature and then diluted with dichloromethane (DCM),
and the resulting solution was washed with 5% aqueous Na2CO3. The
organic layer was isolated and dried over anhydrous Na2SO4, ﬁltered,
and evaporated to dryness to aﬀord the desired 4-(N-aminoalkyl)-
amino-7-chloroquinoline (6, Scheme 1). Each compound 6 was then
coupled to the respective cinnamic acid in N,N-dimethylformamide
(DMF), using O-(benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium
tetraﬂuoroborate (TBTU) and N,N-diethyl-N-isopropylamine
(DIEA) (Scheme 1). A solution of cinnamic acid (1.1 equiv, 0.22
mmol), TBTU (1.1 equiv, 0.22 mmol), and 2.2 equiv of DIEA (68 μL)
in DMF was stirred at 0 °C for 10 min. A solution of the appropriate
compound 6 (1 equiv, 0.2 mmol) in DMF was then added and the
reaction allowed to proceed at room temperature for 24 h. The
mixture was diluted with DCM, and the resulting solution was washed
with 5% aqueous Na2CO3. The organic layer was separated, dried over
anhydrous Na2SO4, ﬁltered, and evaporated to dryness, and the crude
product was puriﬁed by liquid chromatography on silica using EtOAc/
MeOH, 8:2 (v/v), to give the desired compounds 9 and 10. In the
particular case of 9e, 4-(N-aminopropyl)amino-7-chloroquinoline was
ﬁrst coupled to p-(N-tert-butoxycarbonyl)aminocinnamic acid as
above, to yield the N-tert-butoxycarbonyl (Boc) protected precursor
(9e′), followed by removal of Boc through acidolysis with neat
triﬂuoroacetic acid (TFA). Spectral/analytical data on compounds 9
and 10 follow.
4-(N-Cinnamoylaminopropyl)amino-7-chloroquinoline (9a).
White solid (32 mg, 42%); mp 174−192 °C; Rf (EtOAc/MeOH 8:2)
0.25; δH (400 MHz, DMSO-d6) 8.39 (d, J = 5.6 Hz, 1H), 8.27 (m,
2H), 7.79 (d, J = 2.4 Hz, 1H), 7.46 (m, 8H), 6.67 (d, J = 15.6 Hz, 1H),
6.49 (d, J = 5.6 Hz, 1H), 3.32 (m, 4H), 1.89 (m, 2H); δC (100 MHz,
DMSO-d6) 172.0, 165.1, 151.9, 150.0, 149.0, 138.5, 134.8, 133.3,
129.3, 128.8, 127.4, 127.4, 124.0, 122.1, 117.4, 98.6, 40.0, 36.6, 27.8.
ESI-IT MS: m/z 366.47 (M + H+), M+ (C21H20ClN3O) requires
365.13. HPLC-DAD: tR = 13.0 min, % area = 100.
4-[N-(p-Methyl)cinnamoylaminopropyl]amino-7-chloroqui-
noline (9b). White solid (53 mg, 68%); mp 204−209 °C; Rf (EtOAc/
MeOH 8:2) 0.25; δH (400 MHz, DMSO-d6) 8.39 (d, J = 5.6 Hz, 1H),
8.27 (d, J = 9.2 Hz, =1H), 8.22 (m, 1H), 7.79 (d, J = 2.4 Hz, 1H), 7.40
(m, 5H), 7.20 (d, J = 8 Hz, 2H), 6.60 (d, J = 16 Hz, 1H), 6.48 (d, J =
5.6 Hz, 1H), 3.32 (m, 4H), 2.30 (s, 3H), 1.87 (m, 2H); δC (100 MHz,
DMSO-d6) 165.2, 151.8, 149.9, 149.0, 139.1, 138.5, 133.3, 132.1,
129.4, 127.4, 127.4, 124.0, 121.0, 117.4, 98.6, 39.4, 36.6, 27.8, 20.8.
ESI-IT MS: m/z 380.4 (M + H+) M+ (C22H22ClN3O) requires 379.15.
HPLC-DAD: tR = 14.0 min, % area = 100.
4-[N-(p-Isopropyl)cinnamoylaminopropyl]amino-7-chloro-
quinoline (9c). White solid (28.7 mg, 33%); mp 173−178 °C; Rf
(EtOAc/MeOH 8:2) 0.25; δH (400 MHz, DMSO-d6) 8.39 (d, J = 5.2
Hz, 1H), 8.27 (d, J = 9.2 Hz, =1H), 8.22 (m, 1H), 7.79 (d, J = 2.4 Hz,
1H), 7.40 (m, 5H), 7.27 (d, J = 8 Hz, 2H), 6.59 (d, J = 15.6 Hz, 1H),
6.48 (d, J = 5.6 Hz, 1H), 3.32 (m, 4H), 2.89 (m,1H), 1.86 (m, 2H),
1.19 (d, J = 6.8 Hz, 6H); δC (100 MHz, DMSO-d6) 165.2, 151.8,
150.0, 149.9, 149.0, 138.5, 133.3, 132.5, 127.5, 127.5, 126.8, 124.0,
121.1, 117.4, 98.6, 40.0, 36.6, 33.2, 27.8, 23.6. ESI-IT: m/z 408.47 (M
+ H+), M+ (C24H26ClN3O) requires 407.18. HPLC-DAD: tR = 16.0
min, % area = 94.9.
4-[N-(p-Methoxy)cinnamoylaminopropyl]amino-7-chloro-
quinoline (9d). White solid (15 mg, 7%); mp 178−180 °C; Rf
(EtOAc/MeOH 8:2) 0.25; δH (400 MHz, DMSO-d6) 8.39 (d, J = 5.6
Hz, 1H), 8.28 (d, J = 9.2 Hz, =1H), 8.18 (m, 1H), 7.79 (d, J = 2.4 Hz,
1H), 7.44 (m, 5H), 6.97 (d, J = 8.8 Hz, =2H), 6.51 (m, 2H), 3.78 (s,
3H), 3.32 (m, 4H), 1.85 (m, 2H); δC (100 MHz, DMSO-d6) 172.0,
165.4, 160.2, 151.6, 150.1, 148.7, 138.2, 133.4, 129.0, 127.4, 127.2,
124.0, 119.6, 117.4, 114.2, 98.6, 55.2, 40.0, 36.5, 27.8. ESI-IT MS: m/z
396.53 (M + H+), M+ (C22H22ClN3O2) requires 395.14. HPLC-DAD:
tR = 13.1 min, % area = 98.0.
4 - { N - [ p - ( N - t e r t - B u t o x y c a r b o n y l ) a m i n o ] -
cinnamoylaminopropyl}amino-7-chloroquinoline (9e′). White
solid (124.5 mg, 41%); mp 218−220 °C; Rf (EtOAc/MeOH 8:2) 0.1;
δH (400 MHz, DMSO-d6) 9.54 (s, 1H), 8.39 (d, J = 5.6 Hz, 1H), 8.27
(d, J = 8.8 Hz, 1H), 8.15 (m, 1H), 7.78 (d, J = 2.4 Hz, 1H), 7.46 (m,
5H), 7.34 (m, 2H), 6.49 (m, 2H), 3.32 (m, 4H), 1.85(m, 2H), 1.48 (s,
9H); δC (100 MHz, DMSO-d6) 165.3, 152.5, 151.8, 149.9, 149.0,
140.7, 138.3, 133.3, 128.5, 128.1, 127.4, 124.0, 123.9, 119.9, 118.0,
98.6, 79.3, 40.0, 36.5, 28.0, 27.8. ESI-IT: m/z 481.33 (M + H+), M+
(C26H29ClN4O3) requires 480.19. HPLC-DAD: tR = 15.0 min, % area
= 100.
4-[N-(p-Amino)cinnamoylaminopropyl]amino-7-chloroqui-
noline (9e). White solid (28.8 mg, 73%); mp 103−105 °C; Rf
(EtOAc/MeOH 8:2) 0.1; δH (400 MHz, DMSO-d6) 8.39 (d, J = 5.2
Hz, 1H), 8.27 (d, J = 9.2 Hz, =1H), 8.0 (m, 1H), 7.79 (d, J = 2 Hz,
1H), 7.44 (dd, J = 8.8 Hz, 2 Hz, 1H), 7.29 (m, 4H), 6.56 (d, J = 8.4
Hz, 2H), 6.48 (d, J = 5.6 Hz, 1H), 6.29 (d, J = 15.6 Hz, 1H), 5.55 (b,
2H), 3.29 (m, 4H), 1.84 (m, 2H); δC (100 MHz, DMSO-d6) 166.0,
151.8, 150.4, 150.0, 149.0, 139.4, 133.3, 129.0, 127.4, 124.0, 122.1,
117.4, 115.7, 113.6, 98.6, 40.0, 36.5, 27.9. ESI-IT MS: m/z 381.40 (M
+ H+), M+ (C21H21ClN4O) requires 380.14. HPLC-DAD: tR = 8.65
min, % area = 96.0.
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4-[N-(m-Fluoro)cinnamoylaminopropyl]amino-7-chloroqui-
noline (9f). White solid (36 mg, 45%); mp 185−190 °C; Rf (EtOAc/
MeOH 8:2) 0.25; δH (400 MHz, DMSO-d6) 8.39 (d, J = 5.2 Hz, 1H),
8.27 (m, 2H), 7.79 (d, J = 2 Hz, 1H), 7.41 (m, 6H), 7.20 (m, 1H),
6.67 (d, J = 16 Hz, 1H), 6.48 (d, J = 5.6 Hz, 1H), 3.33 (m, 4H), 1.87
(m, 2H); δC (100 MHz, DMSO-d6) 172.7, 164.8, 163.6, 161.2, 151.8,
150.0, 149.0, 137.4, 137.2, 133.3, 130.7, 127.4, 124.0, 123.6, 117.4,
115.9, 113.8, 98.6, 40.0, 36.7, 27.7. ESI-IT MS: m/z 384.40 (M + H+),
M+ (C21H19ClFN3O) requires 383.12. HPLC-DAD: tR = 13.4 min, %
area = 100.
4-[N-(p-Fluoro)cinnamoylaminopropyl]amino-7-chloroqui-
noline (9g). White solid (27 mg, 34%); mp 187−193 °C; Rf (EtOAc/
MeOH 8:2) 0.25; δH (400 MHz, DMSO-d6) 8.39 (d, J = 5.2 Hz, 1H),
8.28 (m, 2H), 7.78 (d, J = 2.4 Hz, 1H), 7.61 (m, 2H), 7.42 (m, 2H),
7.23 (m, 2H), 6.59 (d, J = 16 Hz, 1H), 6.48 (d, J = 4.8 Hz, 1H), 3.32
(m, 4H), 1.87 (m, 2H); δC (100 MHz, DMSO-d6) 172.1, 165.0, 163.8,
161.3, 151.8, 150.0, 149.0, 137.4, 133.3, 129.6, 127.4, 124.0, 122.0,
117.4, 115.9, 98.6, 40.0, 36.6, 27.8. ESI-IT MS: m/z 384.47 (M + H+)
M+ (C21H19ClFN3O) requires 383.12. HPLC-DAD: tR = 13.3 min, %
area = 100.
4-[N-(p-Chloro)cinnamoylaminopropyl]amino-7-chloroqui-
noline (9h). White solid (39 mg, 46%); mp 191−195 °C; Rf (EtOAc/
MeOH 8:2) 0.25; δH (400 MHz, DMSO-d6) 8.39 (d, J = 5.6 Hz, 1H),
8.28 (m, 2H), 7.78 (d, J = 2.4 Hz, 1H), 7.58 (m, 2H), 7.44 (m, 5H),
6.63 (d, J = 15.6 Hz, 1H), 6.49 (d, J = 5.6 Hz, 1H), 3.32 (m, 4H), 1.87
(m, 2H); δC (100 MHz, DMSO-d6) 164.9, 151.7, 150.1, 148.8, 137.2,
133.8, 133.4, 129.1, 128.9, 127.3, 124.1, 124.0, 122.9, 117.4, 98.6, 40.0,
36.6, 27.8. ESI-IT MS: m/z 400.40 (M + H+), M+ (C21H19Cl2N3O)
requires 399.09. HPLC-DAD: tR = 13.4 min, % area = 95.7.
4-[N-(p-Bromo)cinnamoylaminopropyl]amino-7-chloroqui-
noline (9i). White solid (22 mg, 39%); mp 214−219 °C; Rf (EtOAc/
MeOH 8:2) 0.25; δH (400 MHz, DMSO-d6) 8.39 (d, J = 5.2 Hz, 1H),
8.29 (m, 2H), 7.78 (d, J = 2 Hz, 1H), 7.60 (m, 2H), 7.51 (m, 2H),
7.40 (m, 3H), 6.65 (d, J = 16 Hz, 1H), 6.48 (d, J = 5.6 Hz, 1H), 3.32
(m, 4H), 1.86 (m, 2H); δC (100 MHz, DMSO-d6) 164.9, 151.8, 150.0,
149.0, 137.3, 134.1, 133.3, 131.8, 129.4, 127.4, 124.0, 123.0, 122.5,
117.4, 98.6, 40.0, 36.6, 27.7. ESI-IT MS: m/z 446.20 (M + H+) M+
(C21H19ClBrN3O) requires 443.04. HPLC-DAD: tR = 14.7, % area =
100.
(4-[N-(o-Nitro)cinnamoylaminopropyl]amino-7-chloroqui-
noline (9j). White solid (61.7 mg, 72%); mp 190−195 °C; Rf
(EtOAc/MeOH 8:2) 0.25; δH (400 MHz, DMSO-d6) 8.39 (m, 2H),
8.29 (d, J = 9.2 Hz, 1H), 8.03 (d, J = 8 Hz, 1H), 7.69 (m, 5H), 7.44
(dd, J = 9 Hz, 2 Hz, 1H), 7.33 (m, 1H), 6.63 (d, J = 15.6 Hz, 1H), 6.49
(d, J = 5.2 Hz, 1H), 3.33 (m, 4H), 1.89 (m, 2H); δC (100 MHz,
DMSO-d6) 164.2, 151.8, 149.9, 149.0, 148.2, 133.7, 133.5, 133.3,
130.1, 130.0, 128.6, 127.4, 126.8, 124.5, 124.0, 117.4, 98.6, 40.0, 36.7,
27.7. ESI-IT MS: m/z 411.47 (M + H+), M+ (C21H19ClN4O3) requires
410.11. HPLC-DAD: tR = 13.0 min, % area = 100.
4-[N-(m-Nitro)cinnamoylaminopropyl]amino-7-chloroqui-
noline (9k). Yellow solid (22 mg, 25%); mp 209−214 °C; Rf
(EtOAc/MeOH 8:2) 0.25; δH (400 MHz, DMSO-d6) 8.39 (m, 2H),
8.26 (m, 2H), 8.20 (dd, J = 8 Hz, 1.6 Hz, 1H), 8.01 (d, J = 7.6 Hz,
1H), 7.77 (d, J = 2 Hz, 1H), 7.70 (m, 1H), 7.55 (d, J = 15.6 Hz, 1H),
7.44 (dd, J = 8.8 Hz, 2.4 Hz, 1H), 7.34 (m, 1H), 6.82 (d, J = 15.6 Hz,
1H), 6.49 (d, J = 5.6 Hz, 1H), 3.34 (m, 4H), 1.89 (m, 2H); δC (100
MHz, DMSO-d6) 164.5, 151.8, 149.9, 149.0, 148.2, 136.7, 136.2, 133.8,
133.3, 130.4, 127.4, 125.0, 123.8, 123.6, 121.4, 117.4, 98.6, 36.7, 27.7.
ESI-IT MS: m/z 411.40 (M + H+), M+ (C21H19ClN4O3) requires
410.11. HPLC-DAD: tR = 13.2 min, % area = 95.0.
4-[N-(p-Nitro)cinnamoylaminopropyl]amino-7-chloroquino-
line (9l). Yellow solid (42 mg, 49%); mp 200−205 °C; Rf (EtOAc/
MeOH 8:2) 0.25; δH (400 MHz, DMSO-d6) 8.39 (m, 2H), 8.26 (m,
3H), 7.81 (m, 3H), 7.53 (d, J = 15.6 Hz, 1H), 7.45 (d, J = 9 Hz, 2.4
Hz, 1H), 7.35 (m, 1H), 6.81 (d, J = 16 Hz, 1H), 6.49 (d, J = 5.6 Hz,
1H), 3.34 (m, 4H), 1.88 (m, 2H); δC (100 MHz, DMSO-d6) 164.4,
151.7, 150.0, 149.0, 147.4, 141.5, 136.2, 133.4, 128.5, 127.3, 126.4,
124.0, 124.0, 117.4, 98.6, 36.8, 27.8. ESI-IT MS: m/z 411.40 (M + H+)
M+ (C21H19ClN4O3) requires 410.11. HPLC-DAD: tR = 13.2 min, %
area = 96.0.
4-[N-(p-Isopropyl)cinnamoylaminopentyl]amino-7-chloro-
quinoline (10a). White solid (190 mg, 50%); mp = 152−155 °C; Rf
(DCM/MeOH 8:2) 0.58; δH (400 MHz, DMSO-d6) 8.38 (d, J = 5.6
Hz, 1H), 8.28 (d, J = 9.5 Hz, 1H), 8.07 (m, 1H), 7.77 (d, J = 2 Hz,
1H), 7.36 (m, 7H), 6.56 (d, J = 16 Hz, 1H), 6.46 (d, J = 5.6 Hz, 1H),
3.22 (m, 4H), 2.89 (m, 1H), 1.69 (m, 2H), 1.46 (m, 4H), 1.19 (d, J =
6.8 Hz, 6H); δC (100 MHz, DMSO-d6) 164.9, 151.8, 150.0, 149.8,
148.9, 138.2, 133.3, 132.5, 127.4, 127.3, 126.8, 124.0, 123.9, 121.3,
117.3, 98.5, 42.3, 38.5, 33.2, 28.9, 27.4, 24.0, 23.6. ESI-IT MS: m/z (M
+ H+) 436.47, M+ (C26H30ClN3O) requires 435.21. HPLC-DAD: tR =
16.3 min, % area = 98.0.
4-[N-(p-Methoxy)cinnamoylaminopentyl]amino-7-chloro-
quinoline (10b). White solid (100 mg, 27%); mp = 142.144 °C; Rf
(DCM/MeOH 8:2) 0.58; δH (400 MHz, DMSO-d6) 8.38 (d, J = 5.6
Hz, 1H), 8.28 (d, J-9.2 Hz, 1H), 8.01 (m, 1H), 7.77 (d, J = 2 Hz, 1H),
7.39 (m, 4H), 6.96 (d, J = 8.8 Hz, 2H), 6.47 (m, 2H), 3.78 (s, 3H),
3.22 (m, 4H), 1.69 (m, 2H), 1.47 (m, 4H); δC (100 MHz, DMSO-d6)
165.1, 160.1, 151.7, 150.0, 148.9, 138.0, 133.3, 128.9, 127.4, 127.3,
124.0, 123.9, 119.8, 117.3, 114.3, 98.5, 55.1, 42.3, 38.4, 28.9, 27.4, 24.0.
ESI-IT MS: m/z (M + H+) 424.40, M+ (C24H26ClN3O2) requires
423.17. HPLC-DAD: tR = 13.7 min, % area = 100.
(4-[N-(p-Chloro)cinnamoylaminopentyl]amino-7-chloroqui-
noline (10c). Yellowish solid (65 mg, 17%); mp = 164−168 °C; Rf
(DCM/MeOH 8:2) 0.58; δH (400 MHz, DMSO-d6) 8.38 (d, J = 5.2
Hz, 1H), 8.29 (d, J = 8.8 Hz, 1H), 8.16 (m, 1H), 7.77 (d, J = 1 Hz,
1H), 7.56 (d, J = 8.8 Hz, 2H), 7.42 (m, 4H), 7.32 (m, 1H), 6.64 (d, J =
16 Hz, 1H), 6.44 (d, J = 5.2 Hz, 1H), 3.22 (m, 4H), 1.68 (m, 2H),
1.51 (m, 2H), 1.41 (m, 2H); δC (100 MHz, DMSO-d6). ESI-IT MS:
m/z (M + H+) 428.53, M+ (C23H23Cl2N3O) requires 427.12. HPLC-
DAD: tR = 14.9, % area = 100.
Synthesis of Compound 11. 4-[(7-Chloroquinolin-4-yl)-
amino]butan-1-ol (11′). An amount of 1 equiv of 4,7-dichloroquino-
line (0.5g, 2.5 mmol) was mixed with 4 equiv of 4-aminobutan-1-ol
(0.9g, 10 mmol) in a round-bottom ﬂask, and the reaction was allowed
to proceed at 100 °C for 4 h. Then DCM (25 mL) was added,
followed by addition of 30% aqueous Na2CO3 (25 mL), with
concomitant precipitation of a light pink solid. The solid was
submitted to column chromatography on silica, using DCM/MeOH
(8:2 v/v) as eluent, and pure 11′ was obtained as a white solid (0.49 g,
78%); mp = 171−174 °C; Rf = 0.26 (DCM/MeOH 8:2); δH (400
MHz, DMSO-d6); 8.38 (d, J = 5.2 Hz, 1H), 8.27 (d, J = 9.2 Hz, 1H),
7.77 (d, J = 2.4 Hz, 1H), 7.42 (dd, J = 9.2 Hz, 2.4 Hz, 1H), 7.32 (m,
1H), 6.44 (d, J = 5.6 Hz, 1H), 4.51 (b, 1H), 3.46 (m, 2H), 3.26 (m,
2H), 1.69 (m, 2H), 1.54 (m, 2H); δC (100 MHz, DMSO-d6) 151.8,
150.0, 149.0, 133.2, 127.4, 124.0, 123.9, 117.4, 98.5, 60.4, 42.2, 30.0,
24.4. ESI-IT MS: m/z (M + H+) 251.33, M+ (C13H15ClN2O) requires
250.09.
4-[N-(p-Methoxy)cinnamoyloxypropyl]amino-7-chloroqui-
noline (11). An amount of 1 equiv of p-methoxycinnamoyl chloride
(0.08 g, 0.4 mmol) was reacted with 1 equiv of 11′ (0.1 g, 0.4 mmol)
in reluxing DCM (2 mL) in the presence of 2 equiv of triethylamine
(112 μL). The solution turned yellow after 10 min, and the reaction
ran for 24 h. The organic layer was washed with 5% aqueous Na2CO3
(3 × 2 mL), dried with anhydrous Na2SO4, ﬁltered, and led to dryness
on a rotary evaporator. The residue was submitted to column
chromatography on silica, using DCM/Me2CO (1:1 v/v) as eluent to
yield 11 as a white solid (34 mg, 21%); mp = 129−134 °C; Rf (DCM/
Me2CO 1:1) 0.26; δH (400 MHz, CDCl3) 8.49 (d, J = 5.2 Hz, 1H),
7.93 (d, J = 2 Hz, 1H), 7.71 (d, J = 9.2 Hz, 1H), 7.63 (d, J = 16 Hz,
1H), 7.43 (d, J = 8.4 Hz, 2H), 7.31 (d, J = 8.8 Hz, 1H), 6.88 (d, J = 8.4
Hz, 2H), 6.39 (d, J = 5.2 Hz, 1H), 6.28 (d, J = 16 Hz, 1H), 5.38 (m,
1H), 4.27 (m, 2H), 3.82 (s, 3H), 3.36 (m, 2H), 1.89 (m, 4H); δC (100
MHz, CDCl3) 167.3, 161.4, 151.7, 149.8, 148.8, 144.7, 134.9, 129.7,
128.4, 126.9, 125.3, 121.1, 117.1, 115.1, 114.3, 99.0, 63.7, 55.3, 42.9,
26.5, 25.3. ESI-IT MS: m/z (M + H+) 411.33, M+ (C23H23ClN2O3)
requires 410.14. HPLC-DAD: tR = 15.4 min, % area = 97.0.
4-[N-(p-Isopropyl)cinnamoylaminopropyl]aminoquinoline
(12). Following the experimental procedure previously described for
compounds 9 and 10 and starting from 4-chloroquinoline (0.25 g, 1.5
mmol) instead of 4,7-dichloroquinoline, 12 was obtained as a beige
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solid (55 mg, 11%): mp = 73−78 °C; Rf (DCM/MeOH 8:2) 0.30; δH
(400 MHz, CDCl3) 8.41 (d, J = 5.6 Hz, 1H), 8.02 (d, J = 8.4 Hz, 1H),
7.95 (d, J = 8.4 Hz, 1H), 7.60 (m, 2H), 7.39 (m, 3H), 7.18 (d, J = 8
Hz, 2H), 6.52 (m, 1H), 6.46 (d, J = 16 Hz, 1H), 6.34 (d, J = 5.6 Hz,
1H), 6.15 (b, 1H), 3.46 (m, 2H), 3.35 (m, 2H), 2.89 (m, 1H), 1.74
(m, 4H), 1.22 (d, J = 6.8 Hz, 6H); δC (100 MHz, CDCl3) 166.7, 150.9,
149.2, 146.6, 141.0, 132.4, 129.7, 128.0, 127.9, 126.9, 125.0, 120.5,
119.7, 118.5, 98.4, 43.1, 39.1, 34.0, 27.8, 25.5, 23.8. ESI-IT MS: m/z
(M + H+) 388.27, M+ (C25H29N3O) requires 387.23. HPLC-DAD: tR
= 15.2 min, % area = 99.0.
Synthesis of Compound 13. N1-(Pyridin-4-yl)butane-1,4-
diamine (13′). An amount of 1 equiv of 4-chloropyridine (0.5 g,
3.3 mmol) was reacted with 10 equiv of butane-1,4-diamine (2.9 g, 33
mmol) in a round-bottom ﬂask put under reﬂux for 2 h. After the
reaction mixture was cooled to room temperature, an amount of 25
mL of distilled water was added, and the desired product was extracted
with DCM (3 × 25 mL). The organic layer was dried over anhydrous
Na2SO4, ﬁltered, and led to dryness on a rotary evaporator. This
aﬀorded 13′ as a yellow oil (0.22 g, 40%). ESI-IT MS: m/z (M + H+)
166.33, M+ (C9H15O3) requires 165.13. Compound 13′ was used
without further puriﬁcation in the synthesis of 13.
4-[N-(p-Methoxy)cinnamoylbutyl]aminopyridine (13). In a
round-bottom ﬂask put at 0 °C, 1.1 equiv of p-methoxycinnamic acid
(0.29 g, 1.5 mmol) was dissolved in DMF (2.5 mL) and activated by
addition of 1.1 equiv of TBTU (0.47 g, 1.5 mmol) and 2 equiv of
DIEA (454 μL). After 10 min, a solution of 1 equiv of 13′ (0.22 g, 1.3
mmol) in DMF (2.5 mL) was added to the previous mixture and the
reaction allowed to proceed for 24 h. Water (25 mL) was added to the
reaction mixture, and the desired product was extracted with DCM (3
× 25 mL). The organic extract was then washed with 5% aqueous
Na2CO3 (3 × 25 mL), dried over anhydrous Na2SO4, ﬁltered, and
taken to dryness on a rotary evaporator. The residue was submitted to
column chromatography on silica, using DCM/MeOH 8:2 (v/v) as
eluent, to aﬀord 13 as a white solid (0.13 g, 30%): mp = 132−136 °C;
Rf = 0.13 (DCM/MeOH 8:2); δH (400 MHz, CDCl3) 8.04 (b, 2H),
7.54 (d, J = 16 Hz, 1H), 7.33 (d, J = 8.8 Hz, 2H), 7.28 (m, 1H), 6.77
(d, J = 8.8 Hz, 2H), 6.36 (m, 3H), 5.14 (m, 1H), 3.73 (s, 3), 3.35 (m,
2H), 3.06 (m, 2H), 1.60 (m, 4H); δC (100 MHz, CDCl3) 166.8, 160.6,
153.7, 149.0, 140.0, 129.1, 127.4, 118.5, 114.1, 107.4, 55.2, 42.1, 39.1,
27.2, 26.0. ESI-IT MS: m/z (M + H+) 326.33, M+ (C19H23N3O2)
requires 325.18. HPLC-DAD: tR = 11.6 min, % area = 100.
Synthes i s o f Compound 14 . N - (N -Phtha loy l ) -
aminobutylmorpholine (14″). An amount of 2 equiv of morpholine
(0.5g, 5.7 mmol) were reacted with 1 equiv of 1-(N-phthaloyl)amino-
4-bromobutane (0.8 g, 2.9 mmol) in reﬂuxing DCM for 24 h, after
which the reaction mixture was washed three times with 5% aqueous
Na2CO3, dried over anhydrous Na2SO4, ﬁltered, and led to dryness in
a rotary evaporator. The residue was submitted to column
chromatography on silica, using as eluent DCM/MeOH (8:2 v/v),
to aﬀord 14′ as a white solid (0.53 g, 64%): mp = 61−63 °C; Rf = 0.67
(DCM/MeOH 8:2); δH (400 MHz, CDCl3) 7.80 (m, 2H), 7.70 (m,
2H), 3.66 (m, 6H), 2.39 (m, 6H), 1.68 (m, 2H), 1.51 (m, 2H); δC
(100 MHz, CDCl3) 168.4, 133.8, 132.1, 123.1, 66.9, 58.3, 53.6, 37.8,
26.4, 23.8. ESI-IT MS: m/z (M + H+) 289.40, M+ (C16H20N2O3)
requires 288.15.
N-Aminobutylmorpholine (14′). An amount of 1 equiv of 14″
(0.1 g, 0.30 mmol) was reacted with 50% ethanolic hydrazine (0.40
mL) for 2 h at room temperature for removal of the phthaloyl N-
protecting group. Water was then added to the reaction mixture, and
the desired product was extracted with DCM (3 × 25 mL). The
organic layer was dried over anhydrous sodium sulfate, ﬁltered, and led
to dryness on the rotary evaporator to aﬀord 14′ as a yellowish oil (25
mg, 45%). ESI-IT MS: m/z (M + H+) 159.27, M+ (C8H18N2O)
requires 158.14. Compound 14′ was used without further puriﬁcation
in the synthesis of 14.
N-(p-Methoxy)cinnamoylaminobutylmorpholine (14). An
amount of 1 equiv of N-aminobutylmorpholine (0.025 g, 0.16
mmol) was immediately used, without further puriﬁcation, in the
coupling with p-methoxycinnamic acid (0.032 g, 0.17 mmol) carried
out as above-described for 13 but using PyBOP (0.088 g, 0.17 mmol)
instead of TBTU as coupling reagent and DCM as a solvent. This
yielded 14 as a white solid (32 mg, 61%): mp = 92−94 °C; Rf (DCM/
MeOH 8:2) 0.52; δH (400 MHz, CDCl3) 7.59 (d, J = 15.6 Hz, 1H),
7.40 (d, J = 8.4 Hz, 2H), 7.20 (d, J = 8.4 Hz, 2H), 6.34 (m, 2H), 3.72
(m, 4H), 3.38 (m, 2H), 2.90 (m, 1H), 2.44 (m, 4H), 2.37 (m, 2H),
1.60 (m, 4H), 1.23 (d, J = 6.8 Hz, 6H); δC (100 MHz, CDCl3) 160.1,
150.7, 140.7, 132.5, 127.7, 126.9, 119.8, 66.9, 58.3, 53.6, 39.5, 34.0,
27.4, 24.0, 23.8. ESI-IT MS: m/z (M + H+) 331.40, M+ (C20H30N2O2)
requires 330.23. HPLC-DAD: tR = 13.2 min, % area = 100.
In Vitro Assays. Blood Stage Activity Assays. The activity of
compounds against cultured P. falciparum was evaluated as previously
reported.11 Brieﬂy, synchronized ring-stage W2 strain P. falciparum
parasites were cultured with multiple concentrations of test
compounds (added from 1000× stocks in DMSO) in RPMI 1640
medium supplemented with 0.5% Albumax (Invitrogen, GIBCO) and
100 μM hypoxanthine. After a 48 h incubation, when control cultures
contained new rings, parasites were ﬁxed with 1% formaldehyde in
PBS, pH 7.4, for 48 h at room temperature and then labeled with 1 nM
YOYO-1 (Molecular Probes) in 0.1% Triton X-100 and 100 mM
ammonium chloride in PBS. Parasitemias were determined from dot
plots (forward scatter vs ﬂuorescence) acquired on a FACSort ﬂow
cytometer using CELLQUEST software (Becton Dickinson). IC50
values for growth inhibition were determined with GraphPad Prism
software from plots of percentages of the level of parasitemia of the
control relative to inhibitor concentration. In each case, goodness of
curve ﬁt was documented by R2 > 0.95.
Inhibition of β-Hematin. The β-hematin inhibition assay was
performed as previously described.27,28 Diﬀerent concentrations (0.1−
1 mM) of test compounds dissolved in DMSO were added in triplicate
to 50 μL of hemin chloride dissolved in DMSO (5.2 mg/mL).
Negative controls were water and DMSO. β-Hematin formation was
initiated by the addition of acetate buﬀer 0.2 M (100 μL, pH 4.4).
Plates were incubated at 37 °C for 48 h, and they were then
centrifuged at 3000 rpm for 15 min (Sigma 3−30 K). After the
supernatant was discarded, the pellet was washed four times with
DMSO (200 μL) and ﬁnally dissolved in 0.2 M aqueous NaOH (200
μL). The solubilized aggregates were further diluted 1:6 with 0.1 M
aqueous NaOH, and absorbances were recorded at 405 nm (Biotek
Powerwave XS with software Gen5 1.07).
Liver-Stage Infection Assays. Inhibition of liver-stage infection by
test compounds was determined by measuring the luminescence
intensity in Huh-7 cells infected with a ﬁreﬂy luciferase expressing P.
berghei line, PbGFP-Luccon, as previously described.
29 Huh-7 cells,
from a human hepatoma cell line, were cultured in 1640 RPMI
medium supplemented with 10% v/v fetal calf serum, 1% v/v
nonessential amino acids, 1% v/v penicillin/streptomycin, 1% v/v
glutamine, and 10 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic
acid (HEPES), pH 7, and maintained at 37 °C with 5% CO2. For
infection assays, Huh-7 cells (1.2 × 104 per well) were seeded in 96-
well plates the day before drug treatment and infection. Medium in the
cells was replaced by medium containing the appropriate concen-
tration of each compound approximately 1 h prior to infection with
sporozoites freshly obtained through disruption of salivary glands of
infected female Anopheles stephensi mosquitoes. Sporozoite addition
was followed by centrifugation at 1700g for 5 min. At 24 h after
infection, medium was replaced by fresh medium containing the
appropriate concentration of each compound. Inhibition of parasite
development was measured 48 h after infection. The eﬀect of the
compounds on the viability of Huh-7 cells was assessed by the
AlamarBlue assay (Invitrogen, U.K.), using the manufacturer’s
protocol.
In Vivo Assays. Evaluation of the in Vivo Antimalarial Eﬀects of
HEFLECINS. Female Swiss Webster mice (n = 5) were infected with
106 P. berghei-infected erythrocytes by ip injection. Two hours later the
treatment was initiated with ip injections of 10, 30, and 100 mg/kg
compounds 7c, 7d, and 7h twice daily for 4 days. Chloroquine was
used as a positive control at 3, 10, and 30 mg/kg ip twice daily. For all
murine malaria experiments, mice were evaluated daily for toxicity and
for parasitemia by evaluation of Giemsa-stained blood smears. Animals
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were sacriﬁced when signiﬁcant toxicity was identiﬁed or when
parasitemias topped 50%.
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